• CONCLUSION: SCTA appears to be an effective alternative to prolong postoperative topical steroid use.
INTRODUCTION
C ataract surgery is one of the most common and most successful surgical interventions today. Yet, from intra and postoperative complications to patient compliance; it is not without issues. Like other types of surgeries, cataract surgery also induces an inflammatory response, commonly anterior segment inflammation and macular oedema. Postoperative regimens to minimise inflammation vary widely among clinicians. Studies [1] [2] have evaluated the efficacy of alternative administrative routes of corticosteroids apart from topical to deliver higher and more stable intraocular concentrations and improve patient compliance. Injection of depot corticosteroids into sub-Tenon's capsule is an established approach of treating various ocular inflammatory diseases [3] [4] . Postoperative topical drops such as NSAIDs (e.g. ketorolac and nepafenac) [5] [6] and steroids (e.g. dexamethasone and prednisolone) [7] have been the mainstay for prophylaxis and treatment of inflammation. Unfortunately, adherence to topical medication regimens is less than ideal [8] . The current study is designed to evaluate the effects of a single subconjunctival triamcinolone acetonide (SCTA) injection to that of topical loteprednol on intraocular pressure (IOP), anterior chamber inflammation and macular oedema post cataract surgery.
SUBJECTS AND METHODS Ethical Approval
This study was conducted at a tertiary eye care centre in Southern India. Institution Ethics committee approval was obtained before commencement of the study and informed consent taken from each participant. The study was performed in accordance with the tenets of the Declaration of Helsinki. It was designed as a randomised prospective interventional s t u d y a n d c o m p r i s e d o f p a t i e n t s w h o u n d e r w e n t phacoemulsification surgery for cataract over duration of 6mo (Figure 1 ). Patients were randomised 1:1 on the basis of simple coin flipping technique. Group A patients were to receive 5 mg SCTA at the end of surgery with topical ketorolac tromethamine (0.5%) and ofloxacin (0.3%) combination 4 times per day for 7d followed by 2 times per day for 2wk. Group B patients were administered tapering topical loteprednol (0.5%) 6-4-3-2-1 times per day for 7d each with ofloxacin (0.3%) and ketorolac tromethamine (0.5%) 4 times per day for 1wk followed by 2 times per day for 2wk. Patients were followed up at 1wk (visit 1), 6wk (visit 2), and 12wk (visit 3) for evaluation of IOP, anterior chamber cells/flare and macular oedema and other adverse events if any. Inclusion/Exclusion Criteria Patients eligible for inclusion were all those who had a cataractous lens according to Lens Opacities Grading System III (LOCS III) [9] . Patients excluded were those who had cataract with grade 5, 6 nuclear colour/ opalescence, a prior history of uveitis or evident intraocular inflammation, suffering from glaucoma, high myopes (axial length >25 mm), known steroid responders, previous ocular surgeries, corneal diseases. Also excluded were patients with diabetes, hypertension and asthma or on any systemic antiinflammatory therapy. In addition, those who developed any intra-operative complications such as posterior capsule rupture, zonular dialysis or those who could not complete the required follow up visits were also to be excluded. Baseline Evaluation Patients were advised not to take any systemic anti-inflammatory drugs during the study period. Preoperative parameters measured were IOP in mm Hg by Non-contact tonometry (NCT; Topcon CT-80, Topcon Corp, Japan). Slit lamp biomicroscopy examination (Topcon SL 1E, Topcon Corp, Japan) was used to rule out the presence of cells/flare in the anterior chamber and macular edema. Best corrected visual acuity (BCVA) using Snellen visual acuity was noted for every patient. Study Medication A vial of triamcinolone acetonide injection (Tricort 10, Cadila Pharmaceuticals) of 1 mL containing 10 mg/mL was used. A 1-mL syringe with 26 gauge needle was utilised to withdraw 0.5 mL (5 mg) which was subsequently injected subconjunctivally at the end of surgery. Surgical Technique Routine phacoemulsification under topical anaesthesia and implantation of a foldable hydrophobic acrylic monofocal 1 piece posterior chamber intraocular lens (Technis 1, Santa Ana, California, AMO Inc., USA) was performed by a single surgeon. After the conclusion of surgery, 5 mg SCTA was injected under the inferior bulbar conjunctiva in patients of Group A ( Figure 2 ). Outcome Measures Follow up visits were advised at 1, 6, and 12wk and BCVA was recorded. Primary outcomes evaluated were IOP, anterior chamber inflammation and cystoid macular oedema. IOP was measured with the help of NCT with the mean of two measurements used for analysis. Anterior chamber cells/flare were evaluated on slit lamp and graded according to Standardization of Uveitis Nomenclature Working Group criteria (SUN) [10] . Macular oedema was assessed clinically and using Spectralis optical coherence tomography (Cirrus HD OCT 4000 comprised of 200 patients. There was no loss to follow up for any patient in either group. The demographics of the study population have been presented in Table 1 . Figure 3 Table 2 . The difference in anterior chamber cells/flare scores between both the groups were not statistically significant at both visit 1 and visit 2 (P=0.82). Among both the groups receiving treatment, there was no evidence of postoperative macular oedema on slit lamp examination which was then confirmed on optical coherence tomography (OCT). There weren't any other abnormal clinically significant ophthalmic findings. Mean size of the SCTA depot at the time of injection was 6.5 mm. On follow up the mean sizes were 3.5 mm at visit 1, 2.25 mm at visit 2 and 1.15 mm at visit 3. Minimal SCH was noted in 5 patients on visit 1 which completely resolved by visit 2. No other local adverse effects like chemosis, congestion, necrosis or ulceration were seen in any of the follow up visits. DISCUSSION With improvement in cataract surgical techniques, the incidence of postoperative inflammation has declined but still persists. To counter it, various modalities are being tested one of which is the subconjunctival injection of steroids immediately after cataract surgery. With increasing incidence of cataracts in recent times, lack of compliance to postoperative topical medications from patients, increasing cost, and patient inconvenience etc. a single subconjunctival injection of steroid could be a viable alternative to postoperative topical steroid use. Our study shows that a single injection of SCTA at the end of an uneventful cataract surgery is equally effective if not more to prolonged topical steroid use. Weijtens et al [11] suggested that periocular injections of corticosteroids induce a higher concentration of the steroidal agent than topical administration. Of particular concern, is the increase in IOP after administration of systemic corticosteroids [12] . But changes in IOP, our main outcome measure were not significant in the group receiving SCTA in comparison to the baseline values. Nine patients had an IOP>21 mm Hg on visit 1 (among those 4 had an IOP>30 mm Hg). Follow up visits showed improvement in IOP values and by visit 3, IOP values of almost all patients returned to their baseline levels, except only 2 patients among Group A who had an IOP>25 mm Hg. Surgical excision of depot injection has been suggested and may be required in patients who have received sub-Tenon's capsule injections of corticosteroids and are not responding to maximal anti-glaucoma therapy [13] . Considering the above, those 2 patients underwent excision of SCTA under topical anaesthesia, the indication being uncontrolled IOP. Post excision, the IOP in these patients promptly reduced to the normal range without requiring any further topical antiglaucoma therapy. Coming to anterior chamber cells/flare, which were graded on the basis of SUN for reporting clinical data; the results showed almost equal distribution with no statistical difference in patients having cells/flare postoperatively in between both Group A and B during visit 1 and visit 2 (P=0.82). Complete resolution of cells/flare was noted by visit 3. Study conducted by Shah and Spalton [14] showed similar course in resolution of cells/flare to almost nil by 12wk. Laser flare meter has been used for the objective assessment of anterior chamber inflammatory activity [15] . Studies conducted by Tan et al [16] and Negi et al [17] using the above mentioned method showed similar results. The postoperative cells/flare counts in our study were clinically insignificant and thus did not warrant any extra treatment in both groups. Macular oedema, a common complication of cataract surgery is best detected using OCT and in particular using the center point thickness parameter [18] [19] . Since OCT can achieve a highresolution measurement of retinal thickness of up to 10 mm, it may be able to detect subtle changes in retinal thickness which is not clinically evident [20] . Macular oedema mostly peaks at around 4 to 6wk after cataract surgery and can also develop several months postoperatively [21] . Macular oedema has been defined as a relative increased diffuse thickening, presenting with or without cystoid abnormalities and with or without visual loss. Among both groups, no patient developed postoperative macular oedema at any follow up visit. Size of SCTA depot at the time of injection was around 6-7 mm. By visit 3 the depot had completely disappeared in greater than 95% patients and the rest had a depot of less than 2 mm. Location and size of the depot was cosmetically acceptable. Conjunctival ischemia and necrosis following periocular/ intraocular injection of triamcinolone acetonide had been reported in adult patients [22] [23] . In our study, minimal SCH was noted in 5 patients at visit 1 which completely resolved by visit 2. Apart from SCH, no other local adverse effects like chemosis, congestion or necrosis/ulceration were noted at any follow up visits. Limitations of our study include lack of laser flare meter measurements for assessment of flare postoperatively, need for longer follow up especially for analysing macular edema. Wider group of patients not assessed in this study e.g. patients falling in our exclusion criteria; for us to confidently advocate safety and efficacy in various scenarios. An evaluation of subjective patient satisfaction or comfort score to assess the patient's perspective regarding the therapeutic modalities could have added value to this study. Advantage of this study included large sample size with a proper follow up of each and every patient. In our opinion, a single subconjunctival injection of triamcinolone acetonide at the end of a routine uneventful phacoemulsification surgery can be a useful alternative to prolonged tapering topical steroid use in preventing intraocular inflammation and macular oedema. Since the number, frequency and duration of instilling eye drops is significantly reduced in the SCTA group it definitely contributes to faster rehabilitation coupled with greater patient comfort. Further studies are needed for detailed analysis and to cover a broader spectrum of patients.
